Baseline Concentration of Direct Oral Anticoagulant and Incidence of Adverse Event Measure And See (MAS)
CompletedOBSERVATIONAL
Enrollment
2,000
Participants
Timeline
Start Date
August 9, 2018
Primary Completion Date
May 30, 2022
Study Completion Date
May 30, 2023
Conditions
Atrial FibrillationAnticoagulant-induced Bleeding
Trial Locations (1)
26100
Sophie Testa, Cremona
All Listed Sponsors
lead
Arianna Anticoagulazione Foundation
OTHER
NCT03803579 - Baseline Concentration of Direct Oral Anticoagulant and Incidence of Adverse Event Measure And See (MAS) | Biotech Hunter | Biotech Hunter